Lymph node staging in lung cancer using [18F]FDG-PET.
Thorac Cardiovasc Surg
; 52(2): 96-101, 2004 Apr.
Article
em En
| MEDLINE
| ID: mdl-15103582
ABSTRACT
BACKGROUND:
Mediastinal lymph node staging is essential to determine treatment options in patients with NSCLC. Positron emission tomography (PET) detects increased glucose uptake in malignant tissue using the glucose analogue 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG). PATIENTS ANDMETHODS:
In the present study were evaluated 155 patients with focal pulmonary tumors who underwent both preoperative computed tomography (CT) and FDG-PET scanning (116 malignant and 39 benign lesions).RESULTS:
Findings in 155 patients included 116 malignant and 39 benign lesions. For N-staging, FDG-PET showed a sensitivity of 88%, a specificity of 91%, and an accuracy of 89%. Corresponding figures for CT were 77%, 76%, and 77%, respectively.CONCLUSIONS:
FDG-PET is an effective, noninvasive method for staging thoracic lymph nodes in patients with lung cancer and is superior to CT scanning in the assessment of hilar and mediastinal nodal metastases. With regard to operability, FDG-PET could differentiate reliable between patients with N1/N2 disease and those with unresectable N3 disease.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Adenocarcinoma
/
Tomografia Computadorizada de Emissão
/
Carcinoma de Células Grandes
/
Carcinoma Pulmonar de Células não Pequenas
/
Compostos Radiofarmacêuticos
/
Fluordesoxiglucose F18
/
Neoplasias Pulmonares
/
Linfonodos
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Observational_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thorac Cardiovasc Surg
Ano de publicação:
2004
Tipo de documento:
Article